Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 6 clinical trials
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Phase II trial combining azacitidine with valproic acid as maintenance therapy post allogeneic stem cell transplantation in patients with high-risk MDS/AML. We hypothesize that adding valproic acid to azacitidine will improve outcomes via both direct anti-tumor and immunologically mediated antitumor response with alloreactive donor lymphocytes, having an additive effect and …

blast cells
valproic acid
  • 04 May, 2021
  • 1 location
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

This phase II trial studies the side effects and best dose of nivolumab and azacitidine with or without ipilimumab when given together and to see how well they work in treating patients with acute myeloid leukemia that has not responded to previous treatment or has returned after a period of …

graft versus host disease
induction therapy
stem cell transplantation
monoclonal antibodies
  • 31 Jan, 2021
  • 1 location
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to …

serum bilirubin level
stem cell transplantation
absolute neutrophil count
  • 31 May, 2021
  • 1 location
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

Glioma are the most commun frequent brain tumour. Mutation of Isocitrate DeHydrogenase IDH1 or IDH2 genes affect 40% of gliomas, mostly grade II and III gliomas. Despite IDH mutated gliomas (IDHm glioma) have a better prognosis compared to the IDH wild type counterparts, they invariably recur after standard treatment with …

  • 26 Jan, 2021
  • 1 location
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

This research study uses special blood cells called multiple tumor-associated antigen (TAA)-specific T cells (a new experimental therapy) to treat patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) which has come back, or may come back, or has not gone away after standard treatment, including an allogeneic hematopoietic …

white blood cell count
blast cells
chromosome abnormality
  • 30 Jun, 2021
  • 2 locations
Action of the Vidaza on the Atrial Fibrillation

'azacytidine (Vidaza, Celgen Inc.) or the 5-aza-2'-deoxycytidine (Decitabine) (Dacogen, Janssen Cilag). Investigators have performed preliminary studies on the effect of Decitabine on DNA methylation and

  • 23 Jan, 2021
  • 3 locations